Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2180

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 3
Chunk 2180
---
 which the Company submitted a plan for regaining compliance. Notwithstanding that applicable
Nasdaq rules provide a 180-day compliance period to regain compliance with the MVPHS Requirement, the plan submitted by the Company in
connection with such hearing, as required by applicable Nasdaq requirements, demonstrated a pathway to compliance with all applicable
deficiencies.

102

On January 17, 2025, the
Nasdaq Panel granted the Company’s request for an extension of the deadline for regaining compliance with Nasdaq listing requirements
to April 22, 2025, subject to Nasdaq Conditions. Pursuant to the Nasdaq Conditions, the Company shall demonstrate compliance with the
Bid Price Requirement and apply to transfer its listing to the Nasdaq Capital Market on or prior to January 22, 2025. The Company is also
required to satisfy the $2.5 million stockholders’ equity requirement of the Nasdaq Capital Market on or prior to April 22, 2025,
submit certain plans to Nasdaq and make certain disclosures.

On February 12, 2025, we
received a letter from Nasdaq confirming that we have regained compliance with the Bid Price Requirement and we have been moved to the
Nasdaq Capital Market, as required by the Nasdaq Panel.

Regaining compliance with the Bid Price Requirement is one of the conditions
set forth by the Nasdaq Panel in its previously disclosed decision granting our request for an extension to regain compliance with certain
Nasdaq continued listing requirements until April 22, 2025. We continue to make progress towards satisfaction of the other conditions.
Nevertheless, as of the date of this Annual Report, the trading price of our Common Stock is below the Bid Price Requirement and we have
not satisfied the $2.5 million stockholder’s equity requirement. We cannot assure you that we will obtain compliance with these
requirements in a timely manner, or at all.

Warrant Issuances

On December 23, 2024, the Company issued warrants to purchase an aggregate
of 84,061 shares of Common Stock, with an exercise price of $5.61 per share, which was the closing price of the Common Stock on Nasdaq
on December 20, 2024, to certain institutional investors as a condition to the exercise of Preferred Warrants held thereby. On January
6, 2025, the Company issued additional warrants to purchase an aggregate of 163,853 shares of Common Stock, with an exercise price of